| Literature DB >> 34198807 |
Shawna V Hudson1,2, Marin Kurti3, Jenna Howard1, Bianca Sanabria1, Kevin R J Schroth4,5, Mary Hrywna4,5, Cristine D Delnevo2,4,5.
Abstract
Despite the recent push for Tobacco 21 legislation in the US and the national adoption of Tobacco 21, there is a paucity of data on the process of policy adoption. To explore the key factors that served as facilitators or challenges to the passage of state T21 laws that apply to the sale of all tobacco products to anyone under 21 years of age, we conducted a comparative, cross-case study in ten states that adopted Tobacco 21 between 2016 and 2019. Stakeholders from selected states were identified via snowball sampling, and interviews were conducted from November 2018 to March 2020. Three primary factors emerged as facilitators to the passage of state T21 laws: (1) increased attention on e-cigarettes as the product driving an overall increase in youth tobacco use and depiction of an "e-cigarette epidemic", (2) having at least one influential policy entrepreneur or champion, and (3) traction from other states or local municipalities passing T21 legislation. Challenges to T21's success included (1) influence of the tobacco industry, (2) the bill's low ranking among legislative priorities, and (3) controversy among advocates and policymakers over bill language. As e-cigarette rates spiked, T21 bills became legislative priorities, traction from other successful efforts mounted, and ultimately, the tobacco industry flipped from opposing to supporting T21 laws. Despite these favorable headwinds, advocates struggled increasingly to pass bills with ideal policy language.Entities:
Keywords: e-cigarettes; health behavior; policy; tobacco
Mesh:
Year: 2021 PMID: 34198807 PMCID: PMC8201309 DOI: 10.3390/ijerph18116096
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1The passage of Tobacco 21 laws, January 2015 to December 2020.
Affiliation of Tobacco 21 case study participants from 10 states (N = 78), November 2018–March 2020.
| Category | No. | (%) |
|---|---|---|
| National advocacy * | 26 | (33%) |
| Regional advocacy | 27 | (35%) |
| Health department staff | 12 | (15%) |
| Policymakers | 11 | (14%) |
| University affiliates/researchers | 2 | (3%) |
| Total | 78 | (100%) |
* Note: National advocacy participants included individuals from the American Heart Association, American Lung Association, American Cancer Society, Campaign for Tobacco Free Kids, and Preventing Tobacco Addiction Foundation.
Summary of state-level facilitators and barriers to state Tobacco 21 laws.
| State | Passage Date/ | Facilitators | Barriers | ||||
|---|---|---|---|---|---|---|---|
| Policy Diffusion | Policy Entrepreneurs | E-cigarette Epidemic | Tobacco Industry Influence | Lack of Priority | Bill Language Controversy | ||
| California | 05/04/16 | N/A | Legislators | Legislators were starting to see signs of the e-cigarette epidemic. | Industry influenced legislators through campaign contributions and quid pro arrangements. | N/A | Health advocates unsuccessfully lobbied against military exemption. |
| New Jersey | 07/21/17 | Minimal local traction, primarily one high profile city. | Legislators | Minimal local traction, primarily one high profile city. N/A | Industry publicly testified against the bill. | N/A | N/A |
| Massachusetts | 07/27/18 | Extensive local traction; 80% of municipalities passed. | Physicians and Legislators | Surge of JUUL use alarmed legislators and school administrators. | Industry posed public opposition through public hearings and advertisements. | Health advocacy groups focused on flavor bans. | Advocates fought the inclusion of preemption in the final bill but were unsuccessful. |
| Virginia | 02/21/19 | N/A | Legislators | Legislators were motivated to prevent addiction and JUUL use. | Bill was strongly supported by Industry, and some evidence that they wrote it and proposed it to legislators at the last minute to minimize opportunity for opposition. | Clean Indoor Air policy was the priority for tobacco advocates at the time T21 was introduced. | Since the bill was introduced at the end of legislative session, advocates had little time to fight the weakest elements of the bill and were unsuccessful in having them removed from the final bill. |
| Vermont | 05/16/19 | Local traction in one influential city contributed momentum to other local action and the state bill. | Physician and Legislators | Increasing use of e-cigarettes by youth in schools could no longer be ignored by legislators. | Industry lobbied against the T21 bill. | N/A | Advocates fought against instituting penalties for possession and purchase and were ultimately unsuccessful. |
| Arkansas | 03/28/19 | No local traction. | Physicians and Legislators | Vaping epidemic alarmed the public and increased news media attention, which influenced legislators. | Industry lobbied extensively in support of weak legislation. | There were competing demands for the attention of health advocacy groups and legislators, notably the opioid epidemic. | Advocates fought the inclusion of preemption and military exemption but failed to keep them out of the final bill. |
| Texas | 06/07/19 | Local traction in one influential city was viewed as litmus test for state bill. | Legislators | The rise in vaping created more political will; legislators were influenced by increased calls from concerned constituents. | Industry lobbied against T21 and promoted messaging about e-cigarettes as harm reduction. | N/A | Some advocates withdrew support for T21 in the end because law included preemption, military exemption, and weak retailer penalty structure. |
| Connecticut | 06/18/19 | Local traction in two influential cities created momentum for other local action and the state bill. | Legislators | The increase in youth vaping along with calls from constituents motivated legislators. | Industry was first in opposition but changed position and negotiated with legislators. | N/A | N/A |
| Washington | 04/05/19 | Local traction in the capital contributed to statewide momentum. | Legislators | Local traction in the capital contributed to statewide momentum. | Industry was initially in opposition and purportedly funded legislators to oppose the bills. Later in the campaign, industry switched positions and provided support for T21. | Tobacco control advocates were initially prioritizing other policies (e.g., taxation, smoke free air laws and fully funded tobacco program). | Advocates unsuccessfully fought the inclusion of preemption in the final bill, as well as a military exemption. |
| Utah | 03/25/19 | Industry supported T21 and played a role in promoting a weak bill. | Legislators | Local traction in two influential cities created momentum and rationale for the state bill. | Statements from the FDA and CDC declaring an epidemic attracted attention from legislators. | N/A | Advocates unsuccessfully fought several elements of the weak bill, including preemption, military exemption, grandfathering, and PUP penalties. |
Note: N/A = Not applicable; preemption occurs when, by legislative or regulatory action, a higher level of government (state or federal) eliminates or reduces the authority of a lower level over a given issue [28].
Facilitators and barriers to passing T21 laws.
| Theme | Representative quotes | |
|---|---|---|
| Facilitators | Policy Diffusion | “And I think there was a lot of concern among state legislators that we were going to have just a very non-uniform policy, that certain cities would be at the current age of 19 and other cities would start passing their own Tobacco 21 regulations, and I think there were some in our legislature who didn’t want those different policies. They didn’t want to have different policies across the state.” (UT, National advocacy) |
| Policy | “And what they [physician champions] were doing was with their white coats, it was incredibly powerful, and they were getting into the communities we hadn’t been in in a while, that we hadn’t been able to move a tobacco agenda forward in.” (MA, Health departments) | |
| Rise of E-cigarette Epidemic | “I think the teen vaping thing, the epidemic – it was alarming and it freaked people out…I bought a JUUL device and took it to the capitol and I was showing it to these people. And I was like, one in five kids in Arkansas are smoking this. It’s not healthy. It’s nicotine. They get hooked on it. And I had all the facts and stuff, and then you have the surgeon general’s warning – not only was that surgeon general warning a big deal, but it also created it where it put this JUUL-ing teen epidemic on their radar.” (AR, National advocacy) | |
| Challenges | Tobacco Industry Influence | “I think Altria was trying to get in front... they’re pushing this weak bill across the nation and I think they were just trying to look like they were doing good for the youth as it related to tobacco products.” (VA, Health Departments) |
| Lack of Priority | “[A]s an evidence-based organization, we only take positions on policies after we have data and research...And when it came to Tobacco 21, we could assume that it would help, but we don’t operate on assumptions…[T]he Institute of Medicine report came out shortly after our legislative session ended. And that gave ACS CAN and some of other national advocacy partners the data and the research that we needed to really take a position of support on Tobacco 21….[T]he first year of the campaign, we were not supportive. Second year, it was one of our top legislative priorities.” (WA, National advocacy) | |
| Controversy over Bill Language | “We ended up having to put in a military exemption, not because anybody liked it or – the bill authors didn’t even support it – but the governor’s office was threatening to potentially veto the bill if it didn’t have a military exemption in it.” (TX, National advocacy) | |